Open label, phase I/II study of combination of lenalidomide, cyclophosphamide and prednisone in patients with relapsed and refractory multiple myeloma

Trial Profile

Open label, phase I/II study of combination of lenalidomide, cyclophosphamide and prednisone in patients with relapsed and refractory multiple myeloma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Nov 2015

At a glance

  • Drugs Cyclophosphamide (Primary) ; Lenalidomide (Primary) ; Prednisone (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 25 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top